Method of treating hyperglycemia

• US 10,639,292 B2
• Filed: 11/03/2018
• Issued: 05/05/2020
• Est. Priority Date: 04/20/2018
• Status: Active Grant

• Current Assignee: Center Laboratories, Inc.
• Original Assignee: Center Laboratories, Inc.
• Inventors: Hsu, Jui-Pao, Shane, Guang-Tzuu, Lee, Meng-Ju, Liao, Yi-Ping, Yeh, Yu-Yin, Chang, Shu-Hsien
• Primary Examiner(s): Lundgren, Jeffrey S
• Assistant Examiner(s): Strong, Tori
• Application Number:
  US16/179,896
• Publication Number:
  US 20190321326A1
• Time in Patent Office: 549 Days
• CPC Class Codes: A61K 31/277 having a ring, e.g. verapamil
• CPC Class Codes: A61K 31/702 Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics

Abstract

Disclosed herein are methods for treating conditions and/or disorders related to hyperglycemia. Such conditions and/or disorders related to hyperglycemia include, but are not limited to, type I, II diabetes mellitus, gestational diabetes, other forms diabetes, and disorders related thereto. In particular, the present invention relates to methods of using (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof and an α-glycosidase inhibitor in the treatment of conditions and/or disorders related to hyperglycemia.

Claims

1. A method of treating a subject having diabetes mellitus and/or disorders related to diabetes mellitus comprising administering to the subject an effective amount of (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof and acarbose, so as to reduce the blood glucose level of the subject.

2. The method of claim 1, wherein the (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof is administered to the subject in the amount of 15 to 1,000 mg/day;

and the acarbose is administered to the subject in the amount of 10 to 1,000 mg/day.

3. The method of claim 2, wherein the (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof is administered to the subject in the amount of 25 to 800 mg/day;

and the acarbose is administered to the subject in the amount of 25 to 600 mg/day.

4. The method of claim 1, wherein the (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof is administered to the subject in single or divided doses 2 or 3 times each day;

while the acarbose is administered to the subject in single or divided doses 2 or 3 times each day.

5. A pharmaceutical composition for the treatment of diabetes mellitus and/or disorders related to diabetes mellitus comprising, (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof, acarbose, and a pharmaceutically acceptable excipient.

6. The pharmaceutical composition of claim 5, wherein the (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof is present in the pharmaceutical composition in the amount of 15 to 1,000 mg;

and the acarbose is present in the pharmaceutical composition in the amount of 10 to 1,000 mg.

7. The pharmaceutical composition of claim 6, wherein the (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof is a is present in the pharmaceutical composition in the amount of 25 to 800 mg;

and the acarbose is present in the pharmaceutical composition in the amount of 25 to 600 mg.

8. The pharmaceutical composition of claim 5, which is administered to the subject in single or divided doses 2 or 3 times each day.